Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology (BHU), Varanasi 221005, India.
Department of Pharmacology and Toxicology, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
Int J Mol Sci. 2022 Sep 3;23(17):10068. doi: 10.3390/ijms231710068.
Triple-negative breast cancer is considered the most aggressive type of breast cancer among women and the lack of expressed receptors has made treatment options substantially limited. Recently, various types of nanoparticles have emerged as a therapeutic option against TNBC, to elevate the therapeutic efficacy of the existing chemotherapeutics. Among the various nanoparticles, lipid-based nanoparticles (LNPs) viz. liposomes, nanoemulsions, solid lipid nanoparticles, nanostructured lipid nanocarriers, and lipid-polymer hybrid nanoparticles are developed for cancer treatment which is well confirmed and documented. LNPs include various therapeutic advantages as compared to conventional therapy and other nanoparticles, including increased loading capacity, enhanced temporal and thermal stability, decreased therapeutic dose and associated toxicity, and limited drug resistance. In addition to these, LNPs overcome physiological barriers which provide increased accumulation of therapeutics at the target site. Extensive efforts by the scientific community could make some of the liposomal formulations the clinical reality; however, the relatively high cost, problems in scaling up the formulations, and delivery in a more targetable fashion are some of the major issues that need to be addressed. In the present review, we have compiled the state of the art about different types of LNPs with the latest advances reported for the treatment of TNBC in recent years, along with their clinical status and toxicity in detail.
三阴性乳腺癌被认为是女性中最具侵袭性的乳腺癌类型，缺乏表达的受体使得治疗选择受到很大限制。最近，各种类型的纳米颗粒作为治疗 TNBC 的一种选择出现了，以提高现有化疗药物的治疗效果。在各种纳米颗粒中，基于脂质的纳米颗粒（LNPs），如脂质体、纳米乳液、固体脂质纳米颗粒、纳米结构脂质载药系统和脂质-聚合物杂化纳米颗粒，已被开发用于癌症治疗，这已得到充分证实和记录。与传统治疗和其他纳米颗粒相比，LNPs 具有多种治疗优势，包括增加载药量、增强时间和热稳定性、降低治疗剂量和相关毒性以及有限的耐药性。除此之外，LNPs 还克服了生理屏障，使治疗药物在靶部位的积累增加。科学界的广泛努力使一些脂质体制剂成为临床现实；然而，相对较高的成本、制剂放大过程中的问题以及更靶向的给药方式是需要解决的一些主要问题。在本综述中，我们详细编译了不同类型 LNPs 的最新进展，包括用于治疗 TNBC 的最新进展及其临床状况和毒性。
